Alto Neuroscience, Inc. (ANRO)
(Delayed Data from NYSE)
$10.85 USD
-0.15 (-1.36%)
Updated Oct 21, 2025 04:00 PM ET
After-Market: $10.85 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ANRO 10.85 -0.15(-1.36%)
Will ANRO be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for ANRO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ANRO
All You Need to Know About Alto Neuroscience, Inc. (ANRO) Rating Upgrade to Buy
ANRO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for ANRO
Analysts’ Top Healthcare Picks: Alto Neuroscience, Inc. (ANRO), Glaukos (GKOS)
Expansion Breakout appears for ANRO after 80.92% move
Alto Neuroscience price target raised to $16 from $10 at Baird
Alto Neuroscience price target raised by $6 at Baird, here's why
Midday Fly By: AWS hit by outage, Kering sells beauty unit